Home/Pipeline/Autologous MSC Therapy

Autologous MSC Therapy

Arthrosis, muscle/ligament/tendon injuries, joint complaints

Pre-clinical/ClinicalActive

Key Facts

Indication
Arthrosis, muscle/ligament/tendon injuries, joint complaints
Phase
Pre-clinical/Clinical
Status
Active
Company

About Oxacell

Oxacell AG is a private, clinical-stage biotech based in Potsdam/Munich, Germany, specializing in advanced therapy medicinal products (ATMPs) using adipose-derived mesenchymal stem cells. The company operates a GMP-certified manufacturing platform and is developing both autologous and allogeneic cell therapies targeting orthopedic, autoimmune, and liver diseases. While likely pre-revenue from product sales, its strategy involves certified collection centers, academic partnerships, and a pipeline progressing through clinical development and regulatory pathways.

View full company profile